GHK-Cu

GHK-Cu is a copper(II) complex of the naturally occurring tripeptide glycyl-L-histidyl-L-lysine (GHK), first identified in human plasma for its growth-modulating properties Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. It is studied primarily for tissue repair, wound healing, and skin regeneration, with research extending into anti-inflammatory, antioxidant, and anti-fibrotic effects across multiple organ systems GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration+1. The peptide binds copper with high affinity, acting as a copper chaperone and reprogramming gene expression toward repair pathways Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells+1.

Topical GHK-Cu improved healing in diabetic ulcers in a controlled clinical trial Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl‐<scp>l</scp>‐histidyl‐<scp>l</scp>‐lysine copper, while animal and cell studies consistently show enhanced collagen production, reduced inflammation, and improved oxidative stress balance In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds+3. These findings position GHK-Cu as a multi-target regenerative peptide, though human systemic data remain limited GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.

GHK-Cu's main mechanism is binding copper and delivering it into cells, where it shifts gene expression toward repair and antioxidant programs Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells+1. The peptide forms a stable copper complex that can exchange copper with proteins like albumin, serving as a mobile copper carrier X‐ray and Solution Structures of Cu^IIGHK and Cu^IIDAHK Complexes: Influence on Their Redox Properties+1. Once inside cells, GHK-Cu activates pathways such as Nrf2 antioxidant defense Expression of Glycosaminoglycans and Small Proteoglycans in Wounds: Modulation by the Tripeptide–Copper Complex Glycyl-L-Histidyl-L-Lysine-Cu2+, SIRT1 Glycyl-L-histidyl-L-lysine-Cu2+ attenuates cigarette smoke-induced pulmonary emphysema and inflammation by reducing oxidative stress pathway+1, and suppresses NF-κB and JAK1 inflammatory signaling Glycyl-L-histidyl-L-lysine-Cu2(+) (GHK-Cu) Attenuates CuSO(4) or LPS induced-inflammation in Zebrafish larvae model. In wound models, it boosts collagen, glycosaminoglycans, and matrix remodeling enzymes (MMPs) while keeping scar formation in check In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds+2. Animal studies also show mitochondrial protection and activation of stress-resistance pathways linked to healthy aging Middle-aged mice treated with GHK-Cu peptide administered intraperitoneally or intranasally show behavioral rescue but divergent hippocampal aging programs+1.

Research has documented several effects of GHK-Cu:

• Wound healing and skin repair: In a controlled trial, topical GHK-Cu accelerated closure of diabetic foot ulcers Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl‐<scp>l</scp>‐histidyl‐<scp>l</scp>‐lysine copper. Animal models show increased collagen deposition and improved wound healing In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds+2.
• Anti-inflammatory action: In zebrafish and rodent models, GHK-Cu reduced pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and increased anti-inflammatory IL-10 Glycyl-L-histidyl-L-lysine-Cu2(+) (GHK-Cu) Attenuates CuSO(4) or LPS induced-inflammation in Zebrafish larvae model+1. It also lowered oxidative stress markers and boosted antioxidant enzymes Expression of Glycosaminoglycans and Small Proteoglycans in Wounds: Modulation by the Tripeptide–Copper Complex Glycyl-L-Histidyl-L-Lysine-Cu2+.
• Lung and airway protection: In animal studies, GHK-Cu attenuated emphysema, fibrosis, and airway remodeling caused by cigarette smoke, silica dust, or allergens Glycyl-L-histidyl-L-lysine-Cu2+ attenuates cigarette smoke-induced pulmonary emphysema and inflammation by reducing oxidative stress pathway+2. These effects involve SIRT1 and Nrf2 pathways.
• Neuroprotection and cognitive aging: In middle-aged mice, GHK-Cu (intraperitoneal or intranasal) improved behavioral performance and altered hippocampal aging gene programs Middle-aged mice treated with GHK-Cu peptide administered intraperitoneally or intranasally show behavioral rescue but divergent hippocampal aging programs. In vitro, it prevented metal-induced protein aggregation Glycyl-<scp>l</scp>-histidyl-<scp>l</scp>-lysine prevents copper- and zinc-induced protein aggregation and central nervous system cell death <i>in vitro</i>.
• Anti-aging indicators: In C. elegans, GHK-Cu extended lifespan, improved stress resistance, and preserved mitochondrial function The GHK-Cu delays aging in Caenorhabditis elegans via coordinated regulation of mitochondrial function and activation of DAF-16/SKN-1 pathways.
• Hair and scalp: Limited preclinical and formulation studies hint at benefits for hair growth, but strong human data are lacking GHK-Cu Tripeptide: A Multifunctional Cosmeceutical Agent with Advanced Delivery Strategies for Enhanced Topical Efficacy.

Most evidence is from animals or cells; only the diabetic ulcer trial provides direct human efficacy data Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl‐<scp>l</scp>‐histidyl‐<scp>l</scp>‐lysine copper.

Research protocols for GHK-Cu vary depending on the route and goal:

Subcutaneous: Community protocols most often use 1–2 mg once daily for 6–8 weeks for skin, recovery, or anti-inflammatory support. Doses may be split into twice-daily injections of 0.5–1 mg. For localized soft-tissue injuries, 1–2 mg daily near the site for 2–6 weeks is common.

Intranasal: In a mouse study, 15 mg/kg/day intranasally for 8 weeks improved cognitive behavior Middle-aged mice treated with GHK-Cu peptide administered intraperitoneally or intranasally show behavioral rescue but divergent hippocampal aging programs. This route is sometimes used by practitioners for central nervous system targets, but human dosing has not been established.

Topical: Formulations such as liposomal creams or serums are applied 1–2 times daily for skin rejuvenation or wound healing Liposomes as Carriers of GHK-Cu Tripeptide for Cosmetic Application+1. Concentrations are low, often 0.01%–0.1% peptide.

Typical cycles are 4–8 weeks on, followed by 1–4 weeks off, to limit continuous copper exposure and assess durability of benefits. For skin remodeling, longer cycles of up to 12 weeks are used.

No formal human dose-finding study exists; all injectable protocols are based on practitioner experience.

GHK-Cu is supplied as a lyophilized powder that must be reconstituted before injection.

• Preferred diluent: Bacteriostatic water for multi-dose vials, or sterile 0.9% saline if used immediately.
• Mixing: Inject diluent slowly into the vial, aiming the stream against the glass to avoid foaming. Swirl gently; do not shake. Let the powder dissolve completely.
• Storage: Store unopened lyophilized vials at 2–8°C (36–46°F) or frozen at -20°C (-4°F) for longer shelf life Stabilization strategies and advancements in lyophilization to preserve integrity and efficacy of next-generation biologicals. Once reconstituted, keep the solution refrigerated at 2–8°C and protect from light. Use within 14–28 days if using bacteriostatic water, or 7–14 days if using plain sterile water.
• Stability: Copper-containing peptides are sensitive to light and heat; avoid repeated warming. If the solution becomes cloudy, changes color, or shows particles, discard it.

An interactive reconstitution calculator is provided below to help determine volumes and doses.

GHK-Cu's copper-binding nature influences its interactions:

• Antioxidants and thiols: Glutathione directly reduces the Cu(II)GHK complex, forming intermediate thiolate species Intermediate Cu(II)-Thiolate Species in the Reduction of Cu(II)GHK by Glutathione: A Handy Chelate for Biological Cu(II) Reduction. High-dose glutathione or NAC may alter the peptide's redox state. To separate effects, many practitioners space these supplements apart.
• Zinc: Long-term high-dose zinc can lower copper availability. If using >25–40 mg/day of zinc, monitor copper status.
• Anti-inflammatory drugs: Because GHK-Cu suppresses NF-κB and cytokine production in animal models Glycyl-L-histidyl-L-lysine-Cu2+ attenuates cigarette smoke-induced pulmonary emphysema and inflammation by reducing oxidative stress pathway+1, combining it with NSAIDs or corticosteroids could lead to additive anti-inflammatory effects. Use cautiously where infection is a risk.
• Co-chelators: Drugs that chelate copper (e.g., penicillamine) may reduce GHK-Cu activity. Avoid concurrent use.
• With other peptides: GHK-Cu is commonly combined with BPC-157 or TB-500 for soft-tissue repair; no adversarial interactions are documented, but the combination adds complexity. It may also pair with growth hormone secretagogues (CJC-1295, ipamorelin) for recovery, though human data are absent.

Cycling GHK-Cu is common in community protocols, not because of proven tolerance but for practical reasons:

• Continuous copper exposure: Since GHK-Cu carries copper, periodic breaks reduce cumulative copper load.
• Phase-based repair: Short cycles (4 weeks) may suit acute injury, while longer cycles (8–12 weeks) target chronic remodeling, mirroring animal studies that showed duration-dependent gene signatures Middle-aged mice treated with GHK-Cu peptide administered intraperitoneally or intranasally show behavioral rescue but divergent hippocampal aging programs.
• Plateau effects: If improvement stalls after 6–8 weeks, a washout period can reset responsiveness.

Typical cycling patterns:

• 4 weeks on, 1–2 weeks off (general recovery)
• 6–8 weeks on, 2–4 weeks off (skin or connective tissue)
• 8–12 weeks on, 4 weeks off (longer remodeling)

No controlled human studies define optimal cycling; these practices are based on practitioner experience.

GHK-Cu is frequently stacked with other peptides for synergistic repair effects:

• BPC-157 and TB-500: These are the most common stacking partners for soft-tissue and wound healing. GHK-Cu's collagen and matrix remodeling effects complement the angiogenic and healing properties of BPC-157 and TB-500.
• Growth hormone secretagogues (Ipamorelin, CJC-1295, Sermorelin): Combining GHK-Cu with GH boosters may enhance recovery and tissue repair, as GH stimulates IGF-1 while GHK-Cu works on matrix and antioxidant defense. No human trials confirm this synergy.
• SS-31 or MOTS-c: For mitochondrial health and oxidative stress, GHK-Cu's antioxidant effects pair well with mitochondrial-targeted peptides.
• Epithalon: Both are studied in anti-aging contexts; GHK-Cu focuses on repair and copper biology, while Epithalon may modulate telomerase and pineal function.

Stacking should be approached with caution, as no controlled trials validate these combinations. Use one new peptide at a time to assess tolerance.

GHK-Cu is not FDA-approved as a prescription drug in the United States Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance+1. It is primarily sold as a cosmetic ingredient (often listed as Copper Tripeptide-1) in topical skin care products and as an investigational compound for research purposes. The peptide has a long history of use in regenerative medicine research and some limited clinical wound-healing studies Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl‐<scp>l</scp>‐histidyl‐<scp>l</scp>‐lysine copper, but no injectable form has received regulatory approval.

Outside the U.S., GHK-Cu remains unapproved as a medicinal product in the EU, UK, and Australia Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells+1. It is sometimes available through compounding pharmacies or aesthetic clinics, but its legal status varies by jurisdiction. Athletes should note that unapproved injectable peptides may be considered prohibited under WADA's blanket clause (S0); competitors should verify with their sport's anti-doping body Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

GHK-Cu's safety profile is generally favorable in topical and short-term animal studies, but human systemic safety data are sparse Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl‐<scp>l</scp>‐histidyl‐<scp>l</scp>‐lysine copper+2. The main concerns are related to copper handling and injection-site reactions.

• Common effects: Injection-site pain, temporary redness, metallic taste, headache, or nausea are reported by some users. Topical use can cause mild irritation in sensitive skin.
• Copper overload risk: Since GHK-Cu delivers copper, extended high dosing could theoretically raise copper levels. No human toxicity threshold is established; practitioners recommend monitoring serum copper and ceruloplasmin with prolonged use.
• Contraindications: Do not use if you have Wilson disease, known copper overload, or active infection at the injection site. Relative caution is advised in severe liver/kidney impairment, active cancer, or pregnancy (no safety data exist).
• Monitoring: For injectable courses, periodic checks of liver function, complete blood count, and copper status are prudent.

The absence of controlled safety trials means users should be cautious and consult a healthcare provider.